Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Drug Cluster: What Are Global Regulators Discussing?

FDA’s Sarah Ibrahim Outlined Key Generic Drug Topics Among Seven Health Agencies

Executive Summary

In its ongoing attempt to embrace international harmonization, the US Food and Drug Administration invited stakeholders from both sides of the Atlantic to discuss how global health regulators can join forces to improve generic drug development at a recent webinar on “Expanding Generic Drug Access Through International Engagements.”

You may also be interested in...



Celltrion’s Subcutaneous Infliximab Lands On Big PBM Formulary List

One down, two more to go. Celltrion seals a formulary deal with one of the top three PBMs in the US for its subcutaneous infliximab product Zymfentra.

Dr Reddy’s Promotes Drug Access With Three Branded Deals In India

With a clear angle of increasing access to medicines in India, Dr Reddy’s signature landed on three branded deals with pharma firms, bringing more vaccines, cardiovascular and resuscitative drugs to the country.

Open For Business: Sandoz’s Austrian Antibiotic Facility Is Ready To Serve

As Sandoz continues to fight against antimicrobial resistance, the firm opens a new production facility in Austria, strengthening its position in Europe with a vertically integrated production network for penicillin.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153327

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel